Last reviewed · How we verify
AZD2927
AZD2927 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.
AZD2927 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes. Used for Treatment of autoimmune diseases.
At a glance
| Generic name | AZD2927 |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | PI3K delta and PI3K gamma inhibitor |
| Target | PI3K delta and PI3K gamma |
| Modality | Small molecule |
| Therapeutic area | Autoimmune diseases |
| Phase | Phase 2 |
Mechanism of action
By inhibiting these enzymes, AZD2927 aims to modulate the immune response and potentially treat various diseases. The PI3K delta and PI3K gamma enzymes play a role in the activation of immune cells, and their inhibition may help to reduce inflammation and prevent autoimmune diseases.
Approved indications
- Treatment of autoimmune diseases
Common side effects
- Increased risk of infections
Key clinical trials
- A Multi-centre Study Comparing the Effects of AZD2927 and Placebo on the Electrical Activity in the Heart in Patients (PHASE2)
- A Study to Assess the Safety, Tolerability and Pharmacokinetics After Single Ascending Intravenous Doses of AZD2927 in Healthy Male Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |